Blood-Based injection shows promise for slowing dry AMD
NCT ID NCT07428798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether injecting a concentrated form of a patient's own blood, called platelet-rich plasma (PRP), into the eye could slow the progression of advanced dry age-related macular degeneration (AMD). Fourteen people with advanced dry AMD received three PRP injections in one eye, while the other eye was left untreated as a comparison. The goal was to see if the treatment could reduce the growth of damaged areas in the retina and help preserve vision.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Marmara University School of Medicine, Department of Ophthalmology
Istanbul, Istanbul, 34899, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye imaging could reveal hidden clues to vision loss
- A new eye camera may spot stressed cells before vision loss begins
- Gene therapy injection aims to halt blinding eye disease
- Could a daily electric zap to the eye preserve sight in dry AMD?
- Could light therapy help save sight in dry macular degeneration?
- Gene therapy injection aims to treat dry AMD